Clinical trial · Interventional
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
A Prospective,Randomized,Double-Blind,Controlled,Multicenter,Phase III Study of Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Patients With Local Advanced Nasopharyngeal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate nimotuzumab in different indications. Nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in different countries. The Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the clinical efficacy, and safety of the combination of Nimotuzumab administered concomitantly with chemotherapy and radiotherapy in patients with advanced nasopharyngeal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Cancer | Malignant Nasopharyngeal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nimotuzumab | Drug | Nimotuzumab | ALIAS |
| placebo plus chemoradiotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Nimotuzumab plus chemoradiotherapy
- interventionNames
- Drug: Nimotuzumab
- type
- PLACEBO_COMPARATOR
- label
- placebo plus chemoradiotherapy
- interventionNames
- Drug: placebo plus chemoradiotherapy
Primary outcomes (2)
- measure
- To determine the local-regional control rates of the disease in the advanced nasopharyngeal cancer patients subject to the treatment with Nimotuzumab in combination with chemoradiation
- timeFrame
- 3 months after the Nimotuzumab treatment finished
- measure
- To determine the safety of the treatment with Nimotuzumab in combination with chemoradiation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Joined the study voluntary and signed informed consent form * Age 18-70，both genders. * Nasopharyngeal cancer was confirmed by pathology. * Nasopharyngeal cancer 2008 Stages: Ⅲ/Ⅳa. * Primary lesions can measurable. * Karnofsky Performance Scale \>70. * Life expectancy of more than 6 months. * Use of an effective contraceptive method for women when there is a risk of pregnancy during the study. * Haemoglobin≥100g/L ,WBC ≥4×109/L, platelet count≥100×109/L * Hepatic function:ALAT、ASAT\< 1.5 x ULN, TBIL\< 1.5 x ULN * Renal function: Creatinine \< 1.5 x ULN Exclusion Criteria: * Evidence of distant metastasis * Primary lesions or lymph node have been operated (except of operation for biopsy) * Previous radiotherapy * Received other anti EGFR monoclonal antibody treatment * Previous chemotherapy or immunization therapy * Other malignant tumor (except of Non-melanoma Skin Cancer or carcinoma in situ of cervix) * Participation in other interventional clinical trials within 1 month * Peripheral neuropathy is more than I stage * Pregnant or breast-feeding women and women who refused to take contraceptive method * History of serious allergic or allergy * History of Serious lung or heart disease * Refused or can't signed informed consent form * Drug abuse or alcohol addiction * Personality or psychiatric disease, and persons without capacity for civil conduct or persons with limited capacity for civil conduct
References
Publications (0)
Data not yet available